The Week

Edwards Lifesciences (EW) fell 6.15% this week to close at $84.37, underperforming the S&P 500 by roughly 5.35 percentage points (the benchmark slipped 0.8%). The tape was weak throughout: Tuesday’s open at $89.07 gave way to a steady grind lower, with Friday’s low at $83.81 before a modest late-day bounce. The week’s range was 5.93%, while average daily volume of 3.11m shares sat 15.34% below the 60-day median.

Key Events

The biggest company-specific item was the TAVR national coverage decision. Edwards commented on the reimbursement ruling on Wednesday and followed up the next day by reiterating confidence in its 2026 financial guidance. Governance chatter also surfaced early in the week around insider fiduciary duties, and on Friday CVP of TAVR Daniel J. Lippis disclosed selling 619 common shares worth about $54,168.69. Twice during the week the stock underperformed peers.

Analyst Ratings

Across 30 covering institutions, 4 rate the stock a strong buy, 18 a buy, and 7 a hold, with 1 at no opinion; none rate it under or sell. The consensus rating is buy, and the consensus target of $100.96 sits 19.67% above the latest close of $84.37. Targets range from $84.00 to $110.00, a spread of about $26.00, suggesting moderate disagreement. Within the medical devices industry, the company ranks 4th out of 142 names.

The Week Ahead

Macro data takes centre stage next week. Tuesday brings the New York Fed manufacturing index (prior 20.6, forecast 14.75). Wednesday is loaded: retail sales, retail sales ex-autos, import prices, and the NAHB housing market index all land, with headline retail sales prior at -0.6 and forecast at 0.9. A larger miss or beat could swing rate-path expectations. Edwards itself has no earnings due, but follow-through details on the TAVR coverage policy remain on the radar.

In Short

Edwards faced pressure on both price and valuation this week: the 6.15% drop left it trailing the market, while the stock trades near 4.58x book and 48.39x earnings. The latest session’s order flow showed large-lot selling at 76.53% of outflows, with small-lot money on the other side, hinting at a split between institutional and retail positioning. Against that backdrop, consensus ratings stay at buy and the average target sits roughly 19.67% above spot. The tension is between a rich multiple and mixed flow versus a still-supportive sell-side view; the next catalysts are TAVR policy execution and whether retail data shifts broader risk appetite.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.